A dietary supplement, sarcosine, might assist with schizophrenia as a part of a holistic approach complementing antipsychotic treatment, based on a UCL researcher.
In a paper issued in the British Journal of Psychiatry, Professor David Curtis (UCL Genetics, Evolution & Environment and QMUL Centre for Psychiatry) suggests the readily available product may be included into treatment plans, whereas calling for clinical trials to make clear the profit and inform guidelines.
He mentioned, “Sarcosine represents a sound therapy, and the small number of clinical trials to this point does seem to show that it can be useful. It seems to be safe, and a few patients report feeling higher on it.”
“Sarcosine could also be a useful remedy for schizophrenia; however, we should be carrying out further studies to discover out for positive.”
Sarcosine naturally happens in foods such as egg yolks, turkey and legumes, and will be purchased as a dietary supplement, generally promoted as a ‘brain health complement,’ with varied claims being made that aren’t all backed up by enough evidence.
Professor Curtis writes that there’s now good evidence from several strains of study that some patients with schizophrenia might have defects within the functioning of receptors for glutamate, a common neurotransmitter in the brain, and that sarcosine can help glutamate receptors to work higher.
Researchers have been accumulating proof that if these glutamate receptors didn’t function properly, then people might develop psychosis and different signs of schizophrenia.